News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Oct 1, 2016
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based drugs, reported that in its ongoing product portfolio...
-
Jul 4, 2016The technology, developed at the Hebrew University of Jerusalem, facilitates administration and maximal absorption of the active ingredient THC via nasal inhalation
Tel Aviv, Israel. Therapix Biosciences, , (OTCQB: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that...
-
Jun 21, 2016Such technology facilitates the administration and maximal absorption of the active ingredient THC via a sublingual tablet, with a view to provide a response for the indications on which the Company has chosen to focus
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today...
-
Jun 15, 2016The application was filed after completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company’s preparations towards clinical trials in humans
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that it filed...
-
Jun 13, 2016
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that five...